Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil
Serogroup B Neisseria meningitidis is the most common cause of epidemic meningococcal disease in developed countries. Until recently no vaccine has been available for prevention of infection with this organism. In an attempt to control epidemic serogroup B meningococcal disease in greater Sao Paulo, Brazil, during 1989 and 1990, a Cuban-produced outer-membrane-protein-based serogroup B meningococcal vaccine was given to about 2.4 million children aged from 3 months to 6 years. We have done a case-control study to estimate the efficacy of the vaccine in greater Sao Paulo. Microbiologically confirmed cases of serogroup B meningococcal disease were identified through hospital-based surveillance. Controls were matched by neighbourhood and age. Vaccination status was confirmed by inspection of vaccination cards. Between June, 1990, and June, 1991, 112 patients and 409 matched controls with confirmed vaccine status were enrolled. Estimated vaccine efficacy varied by age: 48 months or older = 74% (95% Cl 16 to 92%), 24 to 47 months = 47% (-72 to 84%), and less than 24 months = -37% (< -100 to 73%). Our results suggest that the Cuban-produced vaccine may be effective for prevention of serogroup B meningococcal disease in older children and adults.
| Errataetall: |
ErratumIn: Lancet 1992 Dec 19-26;340(8834-8835):1554 Gral IM [corrected to Landgraf IM] |
|---|---|
| Medienart: |
Artikel |
| Erscheinungsjahr: |
1992 |
|---|---|
| Erschienen: |
1992 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:340 |
|---|---|
| Enthalten in: |
Lancet (London, England) - 340(1992), 8827 vom: 31. Okt., Seite 1074-8 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
de Moraes, J C [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 23.11.1992 Date Revised 10.06.2019 published: Print ErratumIn: Lancet 1992 Dec 19-26;340(8834-8835):1554 Gral IM [corrected to Landgraf IM] Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM01338807X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM01338807X | ||
| 003 | DE-627 | ||
| 005 | 20231221054826.0 | ||
| 007 | tu | ||
| 008 | 231221s1992 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0045.xml |
| 035 | |a (DE-627)NLM01338807X | ||
| 035 | |a (NLM)1357461 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a de Moraes, J C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil |
| 264 | 1 | |c 1992 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 23.11.1992 | ||
| 500 | |a Date Revised 10.06.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a ErratumIn: Lancet 1992 Dec 19-26;340(8834-8835):1554 Gral IM [corrected to Landgraf IM] | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Serogroup B Neisseria meningitidis is the most common cause of epidemic meningococcal disease in developed countries. Until recently no vaccine has been available for prevention of infection with this organism. In an attempt to control epidemic serogroup B meningococcal disease in greater Sao Paulo, Brazil, during 1989 and 1990, a Cuban-produced outer-membrane-protein-based serogroup B meningococcal vaccine was given to about 2.4 million children aged from 3 months to 6 years. We have done a case-control study to estimate the efficacy of the vaccine in greater Sao Paulo. Microbiologically confirmed cases of serogroup B meningococcal disease were identified through hospital-based surveillance. Controls were matched by neighbourhood and age. Vaccination status was confirmed by inspection of vaccination cards. Between June, 1990, and June, 1991, 112 patients and 409 matched controls with confirmed vaccine status were enrolled. Estimated vaccine efficacy varied by age: 48 months or older = 74% (95% Cl 16 to 92%), 24 to 47 months = 47% (-72 to 84%), and less than 24 months = -37% (< -100 to 73%). Our results suggest that the Cuban-produced vaccine may be effective for prevention of serogroup B meningococcal disease in older children and adults | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Adult | |
| 650 | 4 | |a Age Factors | |
| 650 | 4 | |a Americas | |
| 650 | 4 | |a Biology | |
| 650 | 4 | |a Brazil | |
| 650 | 4 | |a Caribbean | |
| 650 | 4 | |a Case Control Studies | |
| 650 | 4 | |a Central Nervous System | |
| 650 | 4 | |a Central Nervous System Effects | |
| 650 | 4 | |a Child | |
| 650 | 4 | |a Control Groups | |
| 650 | 4 | |a Cuba | |
| 650 | 4 | |a Demographic Factors | |
| 650 | 4 | |a Developing Countries | |
| 650 | 4 | |a Diseases | |
| 650 | 4 | |a Infections | |
| 650 | 4 | |a Latin America | |
| 650 | 4 | |a Matched Groups | |
| 650 | 4 | |a Methodological Studies | |
| 650 | 4 | |a North America | |
| 650 | 4 | |a Physiology | |
| 650 | 4 | |a Population | |
| 650 | 4 | |a Population Characteristics | |
| 650 | 4 | |a Prospective Studies | |
| 650 | 4 | |a Research Methodology | |
| 650 | 4 | |a Retrospective Studies | |
| 650 | 4 | |a South America | |
| 650 | 4 | |a Studies | |
| 650 | 4 | |a Urban Population | |
| 650 | 4 | |a Vaccines | |
| 650 | 4 | |a Youth | |
| 650 | 7 | |a Bacterial Outer Membrane Proteins |2 NLM | |
| 650 | 7 | |a Bacterial Vaccines |2 NLM | |
| 650 | 7 | |a Meningococcal Vaccines |2 NLM | |
| 700 | 1 | |a Perkins, B A |e verfasserin |4 aut | |
| 700 | 1 | |a Camargo, M C |e verfasserin |4 aut | |
| 700 | 1 | |a Hidalgo, N T |e verfasserin |4 aut | |
| 700 | 1 | |a Barbosa, H A |e verfasserin |4 aut | |
| 700 | 1 | |a Sacchi, C T |e verfasserin |4 aut | |
| 700 | 1 | |a Landgraf, I M |e verfasserin |4 aut | |
| 700 | 1 | |a Gattas, V L |e verfasserin |4 aut | |
| 700 | 1 | |a Vasconcelos, H de G |e verfasserin |4 aut | |
| 700 | 1 | |a Gral, I M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lancet (London, England) |d 1945 |g 340(1992), 8827 vom: 31. Okt., Seite 1074-8 |w (DE-627)NLM000473936 |x 1474-547X |7 nnns |
| 773 | 1 | 8 | |g volume:340 |g year:1992 |g number:8827 |g day:31 |g month:10 |g pages:1074-8 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 340 |j 1992 |e 8827 |b 31 |c 10 |h 1074-8 | ||